Risk Factors of Anxiety and Depression in Patients With Herpes Zoster Neuralgia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Hospital Anxiety and Depression Scale.
- Who it may be relevant to
- Registry conditions: Herpes Zoster. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Risk Factors Analysis of Anxiety and Depression in Patients With Herpes Zoster Neuralgia and Characteristics of Serum Biomarkers and Functional Brain Magnetic Resonance Changes
Overview
The goal of this observational study is to explore risk factors of anxiety and depression in patients with herpes zoster neuralgia, and the changes of certain serum biomarkers and functional brain magnetic resonance images of these patients.
Detailed description
Patients with herpes zoster neuralgia will be recruited and take Hospital anxiety depression rating scale (Hospital anxiety and 'scale, HADS) evaluation. According to the HADS Scores, patients will be divided into depression group and no depression, or anxiety group and no anxiety group. The clinical data the of two groups will be collected and statistically analyzed to explore the risk factors of anxiety and depression, including the changes of serum biomarkers and functional brain magnetic resonance imaging in patients with herpes zoster neuralgia accompanying anxiety or depression.
Interventions
- Diagnostic test Hospital Anxiety and Depression Scale
Hospital Anxiety and Depression Scale questionnaire is used to test patients for anxiety and depression.
Primary outcome measures
- HADS score [Time frame: during hospital stay, average of 1 week]
Secondary outcome measures (9)
- Interleukin (IL）-1β plasma level [Time frame: during hospital stay, average of 1 week]
- IL-2 receptor plasma level [Time frame: during hospital stay, average of 1 week]
- IL-6 plasma level [Time frame: during hospital stay, average of 1 week]
- IL-8 plasma level [Time frame: during hospital stay, average of 1 week]
- IL-10 plasma level [Time frame: during hospital stay, average of 1 week]
- Interferon(INF)-α plasma level [Time frame: during hospital stay, average of 1 week]
- Brain-derived neurotrophic factor (BDNF) plasma level [Time frame: during hospital stay, average of 1 week]
- C-reactive protein (CRP) plasma level [Time frame: during hospital stay, average of 1 week]
- Area under curve (AUC) of topological metrics of functional brain magnetic resonance imaging [Time frame: during hospital stay, average of 1 week]
Eligibility criteria
Inclusion criteria
- Age more than 18 years old
- Diagnosed as herpes zoster neuralgia
- Signing informed consent
Exclusion criteria
- Unable to complete the scale assessment
- History of mental illness
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
China · 1 center
- Tongji hospital — Wuhan
Publications
- Du J, Sun G, Ma H, Xiang P, Guo Y, Deng Y, Li S, Li X. Prevalence and Risk Factors of Anxiety and Depression in Patients with Postherpetic Neuralgia: A Retrospective Study. Dermatology. 2021;237(6):891-895. doi: 10.1159/000512190. Epub 2020 Dec 16. PMID 33326962
Identifiers
NCT: NCT06449547 · TJ-IRB202401075